Given a context passage, generate a question from the passage such that its answer is shortest continous span from the passage.

Q: The Rams started their season on the road against the Lions. The Rams drew first blood in the first quarter with a 48-yard field goal from Greg Zuerlein to take a 3-0 lead for the only score of that quarter. The Lions then took a 7-3 lead with Joique Bell's 1-yard run for a touchdown in the 2nd quarter. The Rams responded with a 29-yard field goal from Zuerlein as they came up within a point 7-6 before on the Lions' next possession, Matthew Stafford was picked off by Cortland Finnegan and it was returned 31 yards for a touchdown as the Rams retook the lead 13-7. The Lions then responded with Jason Hanson kicking a 41-yard field goal to shorten the Rams' lead to 13-10 at halftime. After the break, the Lions scored first with Jason Hanson kicking a 45-yard field goal to tie the game 13-13 for the only score of the 3rd quarter. However, the Rams moved back into the lead in the 4th quarter with Brandon Gibson's 23-yard catch from Sam Bradford to make it 20-13. The Lions tied the game back up with Kevin Smith running for a touchdown from 5 yards out to tie the game 20-20. The Rams then retook the lead with Greg Zuerlein kicking a 46-yard field goal to make the score 23-20. On their last possession, the Lions moved down the field and Matthew Stafford found Kevin Smith on a 5-yard touchdown pass to make the final score 27-23 as the Rams began their season 0-1.

A: Who kicked the longest field goal in the last quarter?
****
Q: Jonas Valanciunas (Lithuanian pronunciation: (jons vntuns); born 6 May 1992) is a Lithuanian professional basketball player for the Toronto Raptors of the National Basketball Association (NBA).

A: What team is Jonas Valančiūnas on?
****
Q: Patients with lung adenocarcinoma who carry epidermal growth factor receptor (EGFR) gene mutations respond remarkably well to EGFR tyrosine kinase inhibitor (EGFR-TKI), gefitinib, or erlotinib. However, the effect of EGFR-TKI treatment on the prolongation of overall survival (OS) of these patients remains uncertain, although several recent studies have shown prolongation of progression free survival compared with cytotoxic chemotherapy. A total of 304 patients with lung adenocarcinoma who had postoperative recurrent disease were studied. To eliminate potential biases as possible, the matching of four potential predictive factors of responsiveness to EGFR-TKI led to the identification of 81 pairs of patients (those who were treated with gefitinib and those who were not). A deletion mutation in exon 19 and a point mutation (L858R) in exon 21 of the EGFR gene were also analyzed. We compared the OS between the two groups. OS in the gefitinib group was significantly longer than in the control group (median, 63 vs. 41 months; p=0.015). EGFR mutations were detected in 65 out of 129 patients (50%) in the whole sample. EGFR mutational status was not an independent prognostic factor of gefitinib benefit; rather, it was a predictive factor. This study strongly suggested that gefitinib treatment improved OS of lung adenocarcinoma patients who had postoperative recurrence, especially those carrying EGFR mutations.

A:
Mutations in which gene determine response to both erlotinib and gefitinib?
****